European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting

The first ‘Patient and Consumer’ (PCWP) and ‘Healthcare Professionals’ (HCPWP) Working Parties joint meeting of 2022 will begin with an update on COVID-19 vaccines and therapeutics and safety surveillance.

The first day of the meeting will provide an update on EMA projects and initiatives, including:

• accelerating clinical trials in the EU (ACT EU),
• big data;
• electronic product information (ePI);
• the Agency’s extended mandate.

The second day of the meeting will enable discussion on advanced therapy medicinal products (ATMPs) and sharing members’ voices.

The meeting will close with looking ahead to 2022 to 2025.

Day 1

Update on vaccines and therapeutics by M. Cavaleri (EMA)

Safety surveillance on vaccines and therapeutics by P. Bahri (EMA)

Accelerating clinical trials in the EU (ACT-EU) by I. Den Rooijen (EMA)

Big Data Steering Group (BDSG) by J Kaejr (BDSG)

Data Analysis and Real World Interrogation Network (DARWIN-EU) by A. Segec (EMA)

Electronic product information (ePI) by E. Scanlan (EMA)

Engagement and Communication Plan by I. Abed (EMA)

Day 2

Awareness raising on the development and evaluation of ATMPs by Ana Hidalgo, Patrick Celis (EMA)